Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway

Highlights • Addition of ampelopsin to erlotinib dramatically induces apoptosis in erlotinib-resistant NSCLC cells. • Combinational treatment with erlotinib and ampelopsin activates apoptosis through NOX2-dependent ROS-Bim signaling pathway. • A combination strategy with erlotinib and ampelopsin cou...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-04, Vol.106, p.115-124
Hauptverfasser:	Hong, Seung-Woo, Park, Nam-Sook, Noh, Min Hye, Shim, Ju A, Ahn, Byul-Nim, Kim, Yeong Seok, Kim, Daejin, Lee, Hyun-Kyung, Hur, Dae Young
Format:	Artikel
Sprache:	eng
Schlagworte:	Ampelopsin Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis - drug effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor - drug effects Clinical Trials as Topic Combined Modality Therapy - methods Drug Resistance, Neoplasm - genetics Erlotinib Erlotinib Hydrochloride - metabolism Erlotinib Hydrochloride - pharmacology Flavonoids - metabolism Flavonoids - pharmacology Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - pathology Mutation NADPH Oxidase 2 - genetics Nox2 NSCLC Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Reactive Oxygen Species - metabolism Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics RNA, Small Interfering ROS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Addition of ampelopsin to erlotinib dramatically induces apoptosis in erlotinib-resistant NSCLC cells. • Combinational treatment with erlotinib and ampelopsin activates apoptosis through NOX2-dependent ROS-Bim signaling pathway. • A combination strategy with erlotinib and ampelopsin could be used to overcome resistance to erlotinib in NSCLC.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2017.02.009